15800
2017
eng
1489-1498
6
7
article
1
2018-02-23
--
--
Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
C-X-C motif chemokine receptor 4 (CXCR4) and somatostatin receptors (SSTR) are overexpressed in gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In this study, we aimed to elucidate the feasibility of non-invasive CXCR4 positron emission tomography/computed tomography (PET/CT) imaging in GEP-NET patients using [\(^{68}\)Ga]Pentixafor in comparison to \(^{68}\)Ga-DOTA-D-Phe-Tyr3-octreotide ([\(^{68}\)Ga]DOTATOC) and \(^{18}\)F-fluorodeoxyglucose ([\(^{18}\)F]FDG). Twelve patients with histologically proven GEP-NET (3xG1, 4xG2, 5xG3) underwent [\(^{68}\)Ga]DOTATOC, [\(^{18}\)F]FDG, and [\(^{68}\)Ga]Pentixafor PET/CT for staging and planning of the therapeutic management. Scans were analyzed on a patient as well as on a lesion basis and compared to immunohistochemical staining patterns of CXCR4 and somatostatin receptors SSTR2a and SSTR5. [\(^{68}\)Ga]Pentixafor visualized tumor lesions in 6/12 subjects, whereas [\(^{18}\)F]FDG revealed sites of disease in 10/12 and [\(^{68}\)Ga]DOTATOC in 11/12 patients, respectively. Regarding sensitivity, SSTR-directed PET was the superior imaging modality in all G1 and G2 NET. CXCR4-directed PET was negative in all G1 NET. In contrast, 50% of G2 and 80% of G3 patients exhibited [\(^{68}\)Ga]Pentixafor-positive tumor lesions. Whereas CXCR4 seems to play only a limited role in detecting well-differentiated NET, increasing receptor expression could be non-invasively observed with increasing tumor grade. Thus, [\(^{68}\)Ga]Pentixafor PET/CT might serve as non-invasive read-out for evaluating the possibility of CXCR4-directed endoradiotherapy in advanced dedifferentiated SSTR-negative tumors.
Theranostics
10.7150/thno.18754
urn:nbn:de:bvb:20-opus-158008
Theranostics 2017; 7(6): 1489-1498. doi: 10.7150/thno.18754
701983
CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International
Rudolf A. Werner
Alexander Weich
Takahiro Higuchi
Jan S. Schmid
Andreas Schirbel
Michael Lassmann
Vanessa Wild
Martina Rudelius
Theodor Kudlich
Ken Herrmann
Michael Scheurlen
Andreas K. Buck
Saskia Kropf
Hans-Jürgen Wester
Constantin Lapa
eng
uncontrolled
SSTR
eng
uncontrolled
peptide receptor radionuclide therapy
eng
uncontrolled
neuroendocrine tumor
eng
uncontrolled
[\(^{68}\)Ga]Pentixafor
eng
uncontrolled
CXCR4
eng
uncontrolled
chemokine receptor
eng
uncontrolled
PET/CT
eng
uncontrolled
DOTATOC
eng
uncontrolled
PRRT
deu
swd
Positronen-Emissions-Tomografie
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Pathologisches Institut
Medizinische Klinik und Poliklinik II
OpenAIRE
Förderzeitraum 2017
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/15800/Werner_Theranostics.pdf
20186
2019
eng
503
9
article
1
2020-03-16
--
--
[\(^{68}\)Ga]-Pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas
We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [\(^{68}\)Ga]Pentixafor.
Methods: 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [\(^{68}\)Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients.
Results: [\(^{68}\)Ga]Pentixafor PET/CT was visually positive in all cases. SUV\(_{mean}\) and SUV\(_{max}\) were 3.0 ± 0.3 and 3.8 ± 0.4 and TBR\(_{mean}\) and TBR\(_{max}\) were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors.
Conclusion: Non-invasive imaging of CXCR4 expression using [\(^{68}\)Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.
Frontiers in Oncology
10.3389/fonc.2019.00503
urn:nbn:de:bvb:20-opus-201863
Frontiers in Oncology 2019, 9:503. doi: 10.3389/fonc.2019.00503
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Maria Breun
Camelia M. Monoranu
Almuth F. Kessler
Cordula Matthies
Mario Löhr
Carsten Hagemann
Andreas Schirbel
Steven P. Rowe
Martin G. Pomper
Andreas K. Buck
Hans-Jürgen Wester
Ralf-Ingo Ernestus
Constantin Lapa
eng
uncontrolled
vestibular schwannoma
eng
uncontrolled
CXCR4
eng
uncontrolled
PET/CT
eng
uncontrolled
molecular imaging
eng
uncontrolled
Pentixafor
Medizin und Gesundheit
open_access
Neurochirurgische Klinik und Poliklinik
Klinik und Poliklinik für Nuklearmedizin
Pathologisches Institut
Förderzeitraum 2019
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/20186/Breun_fonc-09-00503.pdf